XML 40 R34.htm IDEA: XBRL DOCUMENT v3.24.3
Collaborations - Additional Information (Details)
$ / shares in Units, € in Millions
 1 Months Ended 3 Months Ended 9 Months Ended 12 Months Ended
Mar. 05, 2024
USD ($)
$ / shares
shares
Jan. 18, 2021
USD ($)
$ / shares
shares
Mar. 14, 2018
EUR (€)
Jan. 23, 2017
USD ($)
Jul. 31, 2024
USD ($)
Jan. 31, 2022
Sep. 30, 2024
USD ($)
Milestone
Jun. 30, 2024
USD ($)
Mar. 31, 2024
USD ($)
Sep. 30, 2024
USD ($)
Milestone
Sep. 30, 2023
USD ($)
Dec. 31, 2022
USD ($)
Apr. 30, 2024
USD ($)
Feb. 12, 2021
USD ($)
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                            
Proceeds from issuance of common stock, net                   $ 434,863,000 $ 225,945,000      
Development milestones achieved                   $ 0        
Lilly Collaborations Agreement                            
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                            
Non-refundable upfront payment receivable   $ 40,000,000                        
Issuance of common share, net, shares | shares   706,834                        
Common shares stated purchase price per share | $ / shares   $ 28.295                        
Proceeds from issuance of common stock, net   $ 20,000,000                        
Fixed consideration   43,500,000                       $ 43,500,000
Fee incurred for extension of research term                       $ 500,000    
Extension fee payment of research term received         $ 500,000                  
Upfront payment   40,000,000                        
Net fair value of shares   $ 16,500,000                        
Number of milestones achieved | Milestone             0     0        
Incyte Collaboration and License Agreement                            
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                            
Development milestones achieved             $ 0 $ 0 $ 1,000,000          
Incyte Collaboration and License Agreement | Maximum                            
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                            
Residual royalty percentage           4.00%                
Incyte Collaboration and License Agreement | License and Related Activities                            
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                            
Collaborations, transaction price as deferred revenue       $ 152,600,000                    
Second ONO Research and License Agreement                            
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                            
Non-refundable upfront payment receivable | €     € 0.7                      
Payment to compensate research services | €     0.3                      
Over time payment for full time equivalent funding | €     € 0.2                      
Development milestones achieved             $ 2              
Gilead Collaboration Agreement                            
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                            
Non-refundable upfront payment receivable $ 56,000,000                          
Issuance of common share, net, shares | shares 452,527                          
Common shares stated purchase price per share | $ / shares $ 55.2454                          
Proceeds from issuance of common stock, net $ 25,000,000                          
Fixed consideration 58,400,000                          
Net fair value of shares 22,600,000                          
Non-refundable upfront payment received                         $ 56,000,000  
Number of milestones achieved | Milestone             0     0        
Non-refundable upfront initiation fee 28,000,000                          
License option exercise fee $ 10,000,000